M Oberhoff
Overview
Explore the profile of M Oberhoff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
391
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Oberhoff M, Baumbach A, Herdeg C, Hassenstein S, Xie D, Blessing E, et al.
Lasers Med Sci
. 2010 Aug;
12(4):328-35.
PMID: 20803272
Although the excimer laser, which utilizes 'non-thermal ablation effects', has achieved encouraging results in early clinical trials, the long-term results have failed to show any advantage over conventional percutaneous transluminal...
3.
Oberhoff M, Herdeg C, Al Ghobainy R, Cetin S, Kuttner A, Horch B, et al.
Catheter Cardiovasc Interv
. 2001 Aug;
53(4):562-8.
PMID: 11515014
Paclitaxel is a new cancer chemotherapeutic agent that has been approved for clinical use in patients with a variety of different cancers. Paclitaxel inhibits cell proliferation by an action on...
4.
Schroeder S, Kopp A, Baumbach A, Kuettner A, Herdeg C, Rosenberger A, et al.
Catheter Cardiovasc Interv
. 2001 Jul;
53(3):352-8.
PMID: 11458413
The reliable noninvasive assessment of coronary artery disease would constitute an important step forward in clinical cardiology. The aim of the New Age pilot trial was to evaluate the diagnostic...
5.
Oberhoff M, Kunert W, Herdeg C, Kuttner A, Kranzhofer A, Horch B, et al.
Basic Res Cardiol
. 2001 Jun;
96(3):275-82.
PMID: 11403421
Percutaneous transluminal coronary angioplasty is an accepted treatment for coronary artery disease. The major limitation, however, is the high incidence of restenosis which limits the long-term benefit of this intervention....
6.
Schroeder S, Baumbach A, Herdeg C, Oberhoff M, Buchholz O, Kuettner A, et al.
Eur J Intern Med
. 2001 Apr;
12(2):101-106.
PMID: 11297912
Background: Data on the clinical long-term outcome of patients with coronary artery disease in the years following percutaneous interventions are rare. We therefore decided to conduct a study to: (1)...
7.
Mahrholdt H, Haase K, Baumbach A, Dirr E, Oberhoff M, Schroder S, et al.
Z Kardiol
. 2000 Oct;
89(8):722-9.
PMID: 11013978
Unlabelled: The administration of GP IIb/IIIa antagonists has been shown to be effective in reducing myocardial infarction and cardial death when given before PTCA. This prospective study was performed to...
8.
Herdeg C, Oberhoff M, Siegel-Axel D, Baumbach A, Blattner A, Kuttner A, et al.
Z Kardiol
. 2000 Jul;
89(5):390-7.
PMID: 10900668
Paclitaxel, a potent anti-tumor agent, shifts the cytoskeleton equilibrium towards assembly of altered and extraordinarily stable microtubules. These cellular modifications lead to reduced proliferation, migration, and signal transduction. It is...
9.
Baumbach A, Oberhoff M, Herdeg C, Lerch M, Schroder S, Meisner C, et al.
Basic Res Cardiol
. 2000 Jul;
95(3):173-8.
PMID: 10879618
Background: The low molecular weight heparin Reviparin reduces smooth muscle cell proliferation in cell culture experiments. Clinical studies with systemic application of the substance did not show a reduction of...
10.
Herdeg C, Oberhoff M, Baumbach A, Blattner A, Axel D, Schroder S, et al.
J Am Coll Cardiol
. 2000 Jun;
35(7):1969-76.
PMID: 10841250
Objective: The aim of this study was to evaluate the potential of paclitaxel to prevent restenosis in vivo. Background: Paclitaxel (Taxol) is a microtubule-stabilizing compound with potent antitumor activity. It...